PURPOSE: In 2008, we reported that 10 Japanese-size cups of green tea daily, supplemented with tablets of green tea extract (GTE), reduced the recurrence of colorectal adenoma by 51.6% in patients after polypectomy. Based on these results, we paid special attention to Japanese cancer patients, who consume green tea every day and are administered anticancer drugs. This encouraged us to study whether the combination of green tea catechins and anticancer drugs has the potential to enhance the efficacy of the drugs. RESULTS AND DISCUSSION: The combination of GTE and NSAIDs synergistically inhibited tumor development in rodents through the activation of the GADD153-DR5-TRAIL apoptotic pathway. Since then, this study was further extended by various investigators to the combinations of EGCG and other green tea catechins with anticancer compounds, the latter of which include NSAIDs, phytochemicals, and anticancer drugs. In order to demonstrate whether diversity of the combinations would generally induce synergistic anticancer effects on numerous human cancer cell lines, we studied the results of 42 in vitro combination experiments and the synergistic inhibition of tumor volume of 13 combination experiments using xenograft mouse models, which were previously reported by other investigators. The various combinations of EGCG and anticancer compounds induced similar synergistic anticancer effects for both in vitro and in vivo experiments, and showed an average reduction in tumor volume by 70.3%. Considering the evidence showing that treatment with EGCG inhibited self-renewal of cancer stem cells, the combination shows a great advantage. CONCLUSION: Green tea is a cancer preventive for humans, showing a new trend of green tea catechins as synergists with anticancer compounds.
PURPOSE: In 2008, we reported that 10 Japanese-size cups of green tea daily, supplemented with tablets of green tea extract (GTE), reduced the recurrence of colorectal adenoma by 51.6% in patients after polypectomy. Based on these results, we paid special attention to Japanese cancerpatients, who consume green tea every day and are administered anticancer drugs. This encouraged us to study whether the combination of green tea catechins and anticancer drugs has the potential to enhance the efficacy of the drugs. RESULTS AND DISCUSSION: The combination of GTE and NSAIDs synergistically inhibited tumor development in rodents through the activation of the GADD153-DR5-TRAIL apoptotic pathway. Since then, this study was further extended by various investigators to the combinations of EGCG and other green tea catechins with anticancer compounds, the latter of which include NSAIDs, phytochemicals, and anticancer drugs. In order to demonstrate whether diversity of the combinations would generally induce synergistic anticancer effects on numerous humancancer cell lines, we studied the results of 42 in vitro combination experiments and the synergistic inhibition of tumor volume of 13 combination experiments using xenograft mouse models, which were previously reported by other investigators. The various combinations of EGCG and anticancer compounds induced similar synergistic anticancer effects for both in vitro and in vivo experiments, and showed an average reduction in tumor volume by 70.3%. Considering the evidence showing that treatment with EGCG inhibited self-renewal of cancer stem cells, the combination shows a great advantage. CONCLUSION: Green tea is a cancer preventive for humans, showing a new trend of green tea catechins as synergists with anticancer compounds.
Authors: H Fujiki; M Suganuma; S Okabe; E Sueoka; N Sueoka; N Fujimoto; Y Goto; S Matsuyama; K Imai; K Nakachi Journal: Mutat Res Date: 2001-09-01 Impact factor: 2.433
Authors: Vaqar Mustafa Adhami; Arshi Malik; Najia Zaman; Sami Sarfaraz; Imtiaz Ahmad Siddiqui; Deeba Nadeem Syed; Farrukh Afaq; Farrukh Sierre Pasha; Mohammad Saleem; Hasan Mukhtar Journal: Clin Cancer Res Date: 2007-03-01 Impact factor: 12.531
Authors: Sze Wan Hung; Yiran Li; Xiaoyan Chen; Kai On Chu; Yiwei Zhao; Yingyu Liu; Xi Guo; Gene Chi-Wai Man; Chi Chiu Wang Journal: Front Pharmacol Date: 2022-07-04 Impact factor: 5.988
Authors: Christian Mayr; Andrej Wagner; Daniel Neureiter; Martin Pichler; Martin Jakab; Romana Illig; Frieder Berr; Tobias Kiesslich Journal: BMC Complement Altern Med Date: 2015-06-23 Impact factor: 3.659
Authors: Lidia Hanna Markiewicz; Anna Maria Ogrodowczyk; Wiesław Wiczkowski; Barbara Wróblewska Journal: Nutrients Date: 2021-05-31 Impact factor: 5.717